Business Wire

PopID Closes Equity Financing

Share

Backing from Group of Strategic and Financial Investors Capital Will Facilitate Global Biometric Network

PopID announced an equity financing today including investments from Verifone, PayPal, Commerce Ventures, Chipotle’s Cultivate Next venture fund, and Visa Ventures. This new financing follows previous investments from Cali Group and the Ching family. Over the past several years, PopID has conducted millions of biometric loyalty and payment authentications, proving that face and palm scans for loyalty and payment authentication at the point of sale have unique benefits for consumers and merchants versus phone and card authentication.

“The additional capital will allow us to work with our partners to build critical infrastructure to support an open loop, global biometric network that can connect point of sale solutions to any loyalty program, card payment method, fintech wallet, buy now/pay later platform, stable coin product, or pay-by-bank scheme,” said John Miller, CEO of PopID. “Our group of investing partners includes:

  • Verifone, the global platform powering distinctive payment experiences for all types of businesses;
  • Visa, a world leader in digital payments;
  • PayPal, a leading commerce platform with more than 430 million active accounts;
  • Commerce Ventures, a leading venture capital firm in fintech; and
  • the venture fund of a leading fast casual restaurant company, Chipotle.”

PopID recently announced a partnership with Verifone to retrofit existing Verifone terminals to accept face and palm authentication and embed biometrics in all future Verifone terminals. The joint solution will leverage Verifone’s vast array of existing global assets: 45M devices (15M of which run 200 proprietary payment applications managed by Verifone’s cloud-based device management platform); integrations with 2,500 ECRs/POSs; 150+ payment processors, and acceptance of 40+ global, local, and alternate payment methods.

“Our strategic partnership and investment in PopID furthers our decades-long mission to innovate in the payments space for merchants and consumers,” said Himanshu Patel, Verifone CEO. “Our customers and partners are eager to implement biometric solutions because they are highly secure, convenient and quick. I am confident that together with PopID we will see widespread global adoption of PopID’s technology in the coming years.”

About PopID

PopID provides a comprehensive platform for revolutionizing digital interactions and payments using consumer-initiated biometric verification. PopID’s platform gives consumers the option of identifying themselves quickly and easily – with their face or palm – for checking in, earning loyalty, ordering, and making payments – enabling more personalized, secure, and streamlined experiences. To learn more about PopID and its offerings, visit www.popid.com.

About Verifone

Verifone is a leading global payments technology provider trusted by the world’s top brands. Verifone powers the boundless payments grid—enabling distinctive commerce experiences for merchants, fintech companies, and financial institutions wherever commerce happens. By combining a flexible platform, an open ecosystem of 2,500+ integrations, and four decades of payments expertise, Verifone eliminates payment complexity and expands what’s possible across every payment channel. Each year, Verifone processes $8 trillion in transaction value across 165+ countries around the world helping businesses of all sizes to grow without limits. Learn more at www.verifone.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250604211092/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release

- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc

Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse

Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release

IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release

Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison

Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release

Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye